Danone reports Q2 sales EUR 6.913B vs EUR 6.938B last year

In Q2 2025, sales stood at EUR 6,913m, up +4.1% LFL, led by an increase of +3.2% from volume/mix and +1.0% from price. On a reported basis, sales decreased by -0.4%, due to the negative impact of currencies (-4.9%), reflecting the depreciation of several currencies against the euro, notably the US Dollar, the Mexican Peso, the Chinese Renminbi and the Argentine Peso. Additionally, hyperinflation contributed positively to reported sales (+0.7%), while there was no impact from scope effect. CEO Antoine de Saint-Affrique said, “We started chapter two of the Renew Danone (DANOY) strategy with a strong performance, demonstrating consistency in driving quality growth and reflecting the strength and resilience of our health-focused portfolio: sales for the first half increased by +4.2% on a like-for-like basis, driven by volume-mix up +2.6%. In a volatile and uncertain environment, we are consistently doubling down on our fundamentals, further fueling our winning platforms such as high protein, medical nutrition, Alpro and Aptamil, while moving forward with this next chapter of our strategy. We started actively complementing our portfolio, further investing in medical nutrition, acquiring Kate Farms in the US, and in next-generation biotics through The Akkermansia Company. We remain focused on the consistent execution of our consumer-centric and science-based strategy and the delivery of our mid-term guidance.”